艾滋病的分(fēn)子病毒學(xué)和免疫學(xué)、基因治療及抗病毒藥物(wù)

1、國(guó)家自然科(kē)學(xué)基金重點項目“HIV膜融合機制及強效抑制劑作(zuò)用(yòng)機制的系統研究”（82230076）

2、國(guó)家自然科(kē)學(xué)基金重點項目“HIV感染膜融合的動力學(xué)及分(fēn)子機制研究”（81630061）

3、國(guó)家自然科(kē)學(xué)基金面上項目“新(xīn)型HIV膜融合抑制劑的作(zuò)用(yòng)機制和優化”（81473255）

4、國(guó)家自然科(kē)學(xué)基金面上項目 “HIV融合蛋白M-T鈎子的結構與功能(néng)”（81271830）

5、國(guó)家自然科(kē)學(xué)基金面上項目 “HIV-1融合蛋白核心結構鑒定及新(xīn)型抑制劑設計”（30870123）

6、國(guó)家傑出青年基金項目“醫(yī)學(xué)病毒學(xué)”（81025009）

7、十三五國(guó)家科(kē)技(jì )重大專項“基于強效HIV進入抑制劑的暴露前預防策略研究”(2018ZX10301103)

8.十二五國(guó)家科(kē)技(jì )重大專項“基于廣譜中(zhōng)和抗體(tǐ)的艾滋病功能(néng)性治愈方法究”(2014ZX10001001-001)

9.十一五國(guó)家科(kē)技(jì )重大專項“病原體(tǐ)宿主細胞相互作(zuò)用(yòng)藥物(wù)靶标研究”（2009ZX10004-303）

10.國(guó)家重點研發計劃“I型包膜病毒侵入機制”（2010CB530102）

1、Yanni Gong, Yuxian He. Cell membrane anchoring strategies for HIV gene therapy. Cell Mol Immunol, 2023,20(6):683-685

2、Jing Xue, Huihui Chong, Yuanmei Zhu, Jingjing Zhang, Ling Tong, Jiahan Lu, Ting Chen, Zhe Cong, Qiang Wei, Yuxian He. Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide. Cell, 2022, 185(1): 131-144

3、Yue Chen, Hongliang Jin, Xiaoran Tang, Li Li, Xiuzhu Geng, Yuanmei Zhu, Huihui Chong, Yuxian He. Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targ eting the gp41 fusion protein: new strategies for HIV gene therapy. Emerg Microbes Infect, 2022, 11(1): 30-49

4、Hongliang Jin, Xiaoran Tang, Li Li, Yue Chen, Yuanmei Zhu, Huihui Chong, Yuxian He. Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy. Cell Mol Immunol, 2021, 18(3): 660-674

5、Yuanmei Zhu, Danwei Yu, Yue Hu, Tong Wu, Huihui Chong, Yuxian He. SARS-CoV-2 derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. Signal Transduct Targeted Ther, 2021; 6:294

6、Danwei Yu, Yuanmei Zhu, Yan H, Tong Wu, Huihui Chong, Yuxian He. Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus. Emerg Microbes Infect. 2021; 10(1):810-821

7、Yuanmei Zhu, Danwei Yu, Yang Han, Hongxia Yan, Huihui Chong, Lili Ren, Jianwei Wang, Taisheng Li, Yuxian He. Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recover ed SARS patients and immunized animals. Sci Adv, 2020, 6(45): eabc9999

8、Danwei Yu,Jing Xue, Huamian Wei, Zhe Cong, Ting Chen, Yumei Zhu, Huihui Chong, Qiang Wei, Chuan Qin,Yuxian He. Therapeutic efficacy and resistance selection of a lipopeptide fusion inhibitor in simian immunodeficiency virus -infected rhesus macaques. J Virol. 2020;94(15): e00384-20

9、Yuanmei Zhu, Xiaohui Ding, Danwei Yu, Huihui Chong, Yuxian He. The Tryptophan-Rich Motif of HIV-1 Gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of Gp41 and Its Inhibitors. J Virol. 2020; 94(1): e01358-19

10、Huihui Chong, Jing Xue, Yuanmei Zhu, Zhe Cong, Ting Chen, Qiang Wei, Chuan Qin, Yuxian He. Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppress ion in rhesus macaques. PLoS Pathog, 2019, 15(2): e1007552

1、國(guó)家1類抗HIV新(xīn)藥“利普韋肽”進入II期臨床試驗

2、國(guó)家1類抗HIV新(xīn)藥“注射用(yòng)LP-98”進入I期臨床試驗

3、國(guó)家1類抗SARS-CoV-2新(xīn)藥YKYY017進入II/III期臨床試驗

4、廣譜抗病毒藥物(wù)IPBZS01實現成果轉化并開展Pre-IND研究